GLG News by Fuzeon Prescribers for HIV (US)

Daniel Berger, Clinical Associate Professor of Medicine

Daniel BergerClinical Associate Professor of MedicineUNIVERSITY OF ILLINOIS AT CHICAGO What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Anticipation Surrounds New Single Regimen Tablet, Containing Rilpivirine for HIV

November 17, 2010

Rilpivirine (TMC 278) in Combination with Truvada is Non-Inferior to an Atripla Like Regimen | positivelyaware.com

It has now been some months since 2010 ICAAC; results of the two phase III trials combined, has been sinking in. Rilpivirine when combined with Truvada (Gilead Sciences) was non- inferior to Atripla (Bristol Myers Squibb and Gilead Sciences). Now the salient details are being put into new perspective. We are about to begin a new trial (phase IV) with this new single-tablet formulation which will add to our body of knowledge and examine further use and importance of this single pill regimen.

Daniel Berger, Clinical Associate Professor of Medicine

Daniel BergerClinical Associate Professor of MedicineUNIVERSITY OF ILLINOIS AT CHICAGO What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Egrifta Gains FDA Approval for HIV

November 11, 2010

Egrifta Becomes the First Agent Approved for HIV-Associated Lipodystrophy | www.thebody.com

Egrifta was evaluated in two clinical trials. 816 HIV infected adults with lipodystrophy and excess abdominal fat. 543 patients received Egrifta. In both studies, patients treated with Egrifta experienced greater reductions in abdominal fat (15-17%) measured by CT scan, vs. placebo. . The most commonly reported side effects in the studies included joint pain (arthralgia), skin redness and rash at the injection site (erythema and pruritis), stomach pain, swelling, and muscle pain (myalgia).

Steven FinePhysicianUNIVERSITY OF ROCHESTER MEDICAL CENTER What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Simple potent and safe. This HIV combination will be hard to beat.

August 4, 2006

New AIDS Pill Simplifies Treatment | www.therapeuticsdaily.com

A three drug "cocktail" for treating HIV all in one pill once a day.
The individual components used together but as individual pills have already proven to be among the most potent and safest regimens for patients first starting HIV treatment.
Trials of this combination have not suggested any increase in resistance compared with other combinations.

Page : 11 to 3 of 3

Leading institutions connect with members of the Healthcare councils through GLG

Most Popular Healthcare News